The annualized thrombosis rates in adults appear to be 2–3 times higher with TPO-RA treatment than in an ITP not treated with TPO-RA, and even higher if compared to non-ITP control populations [133,136]. The gene discussed is TPO; the disease is deep vein thrombosis.